Aetiology of inflammatory bowel disease (IBD): Role of intestinal microbiota and gut-associated lymphoid tissue immune response

Clinical Nutrition

Volumn 24, Issue 3, 2005, Pages 339-352

  Thompson Chagoyán, Oscar C ^a   Maldonado, José ^b   Gil, Angel ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Inflammatory bowel disease; Intestinal microbiota; Intestinal tolerance; Probiotics

Indexed keywords

ACETIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BUTYRIC ACID; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DNA; HLA DR1 ANTIGEN; HLA DR2 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; PROPIONIC ACID; TOBRAMYCIN;

ALLELE; APPENDIX; BIFIDOBACTERIUM; CECUM; CHROMOSOME 16; CIGARETTE SMOKING; CLINICAL TRIAL; CYTOKINE PRODUCTION; ENTERITIS; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; LACTOBACILLUS PLANTARUM; MARKER GENE; MENTAL STRESS; NONHUMAN; REVIEW; T LYMPHOCYTE;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINES; LYMPHOID TISSUE; PROBIOTICS;

EID: 18744413253     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2005.02.009     Document Type: Review

References (81)

1. R.S. Blumberg W. Strober Prospects for research in inflammatory bowel disease JAMA 285 2001 643-647
2. J.P. Hugot M. Chamaillard H. Zouali et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease Nature 411 2001 599-603
3. A. Gil Interacciones medio ambiente genes Enfermedad Inflamatoria Intestinal al día 3 2004 38-44
4. A.L. Hart A.J. Stagg M. Frame et al. Review article: The role of the gut flora in health and disease, and its modification as therapy Aliment Pharmacol Ther 16 2002 1383-1393
5. R. Duchmann I. Kaiser E. Hermann W. Mayet K. Ewe K.H. Meyer zum Büschenfelde Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol 102 1995 448-455
6. A. Stallmach T. Marth N. Adrian et al. Increased expression of interleukine-12 receptor beta (2) on lamina propria mononuclear cells of patients with active Crohn's disease Int J Colorectal Dis 17 2002 303-310
7. J. Satsangi K.I. Welsh M. Bunce et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease Lancet 347 1996 1212-1217
8. R.J. Farrell M.A. Peppercorn Ulcerative colitis Lancet 359 2002 331-340
9. M.I. Torres M. Le Discorde P. Lorite et al. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease. Int Immunol 16 2004 579-583
10. R.J. Farrell J.T. La Mont Microbial factors in inflammatory bowel disease Gastroenterol Clin North Am 31 1 2002 41-62
11. R.B. Sartor Pathogenesis and immune mechanisms of chronic inflammatory bowel disease Am J Gastroenterol 2 suppl 1997 5-11
12. F. Casellas N. Borruel M. Papo et al. Anti-inflammatory effects of enterically coated amoxicilin-clavulanic acid in ulcerative colitis Inflamm Bowel Dis 4 1998 1-5
13. J.E. Teitelbaum W.A. Walker Nutritional impact of pre- and probiotics as protective gastrointestinal organisms Annu Rev Nutr 22 2002 107-138
14. A. Swidsinski A. Ladhoff A. Pernthaler et al. Mucosal flora in inflammatory bowel disease Gastroenterology 122 2002 44-54
15. P. Garside A. McI Mowat A. Khoruts Oral tolerance in disease Gut 44 1999 137-142
16. J.D. Taurog J.A. Richardson J.T. Croft et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats J Exp Med 180 1994 2359-2364
17. R.K. Sellon S. Tonkonogy M. Schultz et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin 10-deficient mice Infect Immun 66 1998 5224-5231
18. K.L. Madsen J.S. Doyle L.D. Jewell M.M. Tavernini R.N. Fedorak Lactobacillus species prevents colitis interleukin 10 gene-deficient mice Gastroenterology 116 1999 1107-1114
19. P. Mombaerts E. Mizoguchi M.J. Grusby et al. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice Cell 75 1993 275-282
20. S. Videla J. Vilaseca F. Guarner et al. Role of intestinal microbiota in chronic inflammation and ulceration of the rat colon Gut 35 1994 1090-1097
21. R. Aranda B.C. Sydora P.L. McAllister et al. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients J Immunol 158 1997 3464-3473
22. C. Veltkamp S.L. Tonkonogy Y.P. De Jong et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice Gastroenterology 120 2001 900-913
23. R.I. Mackie A. Sghir H.R. Gaskins Developmental microbial ecology of neonatal gastrointestinal tract Am J Clin Nutr 69 suppl 1999 1035-1045
24. B. Kleesen E. Bezirtzoglou J. Matto Cultured-based knowledge on biodiversity, development and stability of human gastrointestinal microbiota Microb Ecol Health Dis 2 suppl 2000 53-63
25. S. Salminen C. Bouley M.C. Boutron-Ruault et al. Functional food science and gastrointestinal physiology and fuction Br J Nutr 80 suppl 1998 147-171
26. J.M. Saavedra Microbes to fight microbes: A not so novel approach to controlling diarrheal disease J Pediatr Gastroenterol Nutr 21 1995 125-129
27. S. Bengmark Colonic food: Pre- and probiotics Am J Gastroenterol 95 suppl 2000 5-7
28. L.V. Hooper L. Bry P.G. Falk J.I. Gordon Host-microbial symbiosis in the mammalian intestine: Exploring as internal ecosystem Bioessays 20 1998 336-343
29. F. Guarner J.R. Melagelada Gut flora in health and disease Lancet 361 2003 512-519
30. P.G. Falk L.V. Hooper T. Midtvedt J.I. Gordon Creating and maintaining the gastrointestinal ecosystem: What we know and need to know from gnotobiology Microbiol Mol Biol Rev 62 1998 1157-1170
31. M.R. Gismondo L. Drago A. Lombardi Review of probiotics available to modify gastrointestinal flora Int J Antimicrob Agents 12 1999 287-292
32. J.H. Cummings E.R. Beatty S.M. Kingman S.A. Binghman H.N. Englyst Digestion and physiological properties of resistant starch in the human large bowel Br J Nutr 75 1996 733-747
33. E. Miyazawa A. Iwabuchi T. Yoshida Phytate breakdown and apparent absorption of phosphorus, calcium and magnesium in germfree and conventional rats Nutr Res 16 1996 603-613
34. J.I. Gordon L.V. Hoper M.S. McNevin M. Wong L. Bry Epigthelial cell growth and differentiation. III. Promoting diversity in the intestine: conversations between the microbiota, epithelium, and diffuse GALT Am J Physiol 273 1997 565-570
35. C. Guérin-Danan A.F. Popot C.P. Vaissade et al. Pattern of metabolism and composition of the fecal microbiota in infants 10 to 18 months old from day care centers J Pediatr Gastroenterol Nutr 25 1997 281-289
36. E. Bezirtzoglou The intestinal microbiota during the first weeks of life Anaerobe 3 1997 173-177
37. M.F. Bernet D. Brassart J.R. Neeser A.L. Servin Lactobacillus acidophilus LA 1 binds to cultured human cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria Gut 35 1994 483-489
38. R.J. Kennedy S.J. Kirk K.R. Gardiner Promotion for a favorable gut flora in inflammatory bowel disease JPEN 24 2000 189-195
39. N. Borruel M. Carol F. Casellas et al. Increased mucosal TNFα production in Crohn's disease can be modulated in vitro by probiotic bacteria Gut 5 2002 659-664
40. A. Gil ¿Por qué la tolerancia oral? Enfermedad Inflamatoria Intestinal al día 3 2004 66-70
41. G.M. Spiekermann W.A. Walker Oral tolerance and its role in clinical disease J Pediatr Gastroenterol Nutr 32 2001 237-255
42. P.E. Brandtzaeg Current understanding of gastrointestinal immunoregulation and its relation to food allergy Ann NY Acad Sci 964 2002 13-45
43. A.M. Mowat The role of antigen recognition and suppressor cells in mice with oral tolerance to ovoalbumin Immunology 56 1995 253-260
44. A. Miller O. Lider H.L. Weiner Antigen driven bystander suppression after oral administration of antigens J Exp Med 174 1991 791-798
45. J. Sun B. Dirden-Kramer K. Ito P.B. Ernst N. Van Houten Antigen specific T cell activation and proliferation during oral tolerance induction J Immunol 162 1999 5868-5875
46. Y. Chen J. Inobe R. Marks P. Gonella V.K. Kuchroo H.L. Weiner Peripheral deletion of antigen reactive T cells in oral tolerance Nature 376 1995 177-180
47. L. Steidler Microbial and immunological strategies for treatment of inflammatory bowel disease Microb Infect 3 2001 1157-1166
48. A.H. Steinhart A. Brzezinski J.P. Baker Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas Am J Gastroenterol 89 1994 179-183
49. C.M. Hogaboam B.A. Vallance A. Kumar C.L. Addison F.L. Graham Gauldie J. Therapeutic effects of interleukin 4 gene transfer in experimental inflammatory bowel disease J Clin Invest 100 1997 2766-2776
50. T.T. McDonald Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD) Clin Exp Immunol 102 1995 445-447
51. F. Shanahan Therapeutic manipulation of gut flora Science 289 2000 1311-1312
52. H.S. Gill F. Guarner Probiotics and human health: A clinical perspective Postgrad Med J 80 2004 516-526
53. E. Isolauri P.V. Kirjavainen S. Salminen Probiotics: A role in the treatment of intestinal infection and inflammation? Gut 50 suppl 2002 54-59
54. A. Gil R. Rueda Interaction of early diet and the development of the immune system Nutr Res Rev 15 2002 263-292
55. R.B. Sartor H.C. Rath R.K. Sellon Microbial factors in chronic intestinal inflammation Curr Opin Gastroenterol 12 1996 327-333
56. R.O. Ehrhardt B.R. Ludviksson B. Gray M. Naurath W. Strober induction and prevention of colonic inflammation in IL-2 deficient mice J Immunol 158 1997 566-573
57. T. Bamba H. Matsuda M. Endo Y. Fujiyama The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis J Gastroenterol 30 1995 45-47
58. T. Shiba Y. Aiba H. Ashikawa et al. The suppressive effect of Bifidobacteria on Bacteroides vulgatus, a putative pathiogenic microbe in inflammatory bowel disease Microbiol Immunol 47 2003 371-378
59. A. Ventury P. Gionchetti F. Rizzello et al. Impact of the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis Aliment Pharmacol Ther 13 1999 1103-1108
60. H. Kasper Protection against gastrointestinal diseases- Present facts and future developments Int J Food Microbiol 41 1998 127-131
61. Y. Mao S. Nobaeck B. Kasravi et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats Gastroenterology 111 1996 334-344
62. L. O'Mahony M. Feeney S. O'Halloran et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice Aliment Pharmacol Ther 15 2001 1219-1225
63. W. Kruis E. Schültz P. Fric B. Fixa G. Judmaier M. Stolte Double blind comparison of an oral E. coli preparation and mesalazine in maintaining remission of ulcerative colitis Aliment Pharmacol Ther 11 1997 853-858
64. L. Steidler W. Hans L. Schotte et al. Treatment of murine colitis by Lactobacillus lactis secreting interleukin-10 Science 289 2000 1352-1355
65. M. Tvede S. Bondesen O.H. Nielson S.N. Rasmussen Serum antibodies to Bacteroides species in chronic inflammatory bowel disease Scand J Gastroenterol 18 1983 783-789
66. L.V. Hooper M.H. Wong A. Thelin L. Hansson P.G. Falk J.I. Gordon Molecular analysis of commensal host-microbial relationships in the intestine Science 291 2001 881-884
67. F.J. Tedesco R.D. Hardin R.N. Harper B.H. Edwards Infectious colitis endoscopically simulating inflammatory bowel disease: A prospective evaluation Gastrointest Endosc 29 1983 195-197
68. B.J. Rembacken A.M. Snelling P.M. Hawkey D.M. Chalmers A.T.R. Axon Non-pathogenic E. coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial Lancet 354 1999 635-639
69. D.A. Burke A.T. Axon S.A. Clayden M.F. Dixon D. Johnston R.W. Lacey The efficacy of tobramycin in the treatment of ulcerative colitis Amilent Pharmacol Ther 4 1990 123-129
70. R.D. Rolfe The role of probiotic cultures in the control of gastrointestinal health J Nutr 130 suppl 2000 396-402
71. M. Malin H. Soumalainen M. Saxelin E. Isolauri Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG Ann Nutr Metab 40 1996 137-145
72. P. Gupta H. Andrew B.S. Kirschner S. Guandalini Is Lactobacillus GG helpful in children with Crohn's disease. Results of a preliminary, open-label study J Pediatr Gastroenterol Nutr 31 2000 453-457
73. M. Guslandi G. Mezzi M. Sorghi P.A. Testoni Saccharomyces boulardii in maintenance treatment of Crohn's disease Dig Dis Sci 45 2000 1462-1464
74. P. Gionchetti F. Rizzello A. Venturi et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double blind, placebo-controlled trial Gastroenterology 119 2000 305-309
75. A. Venturi P. Gionchetti F. Rizzello et al. Impact of fecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis Aliment Pharmacol Ther 13 1999 1103-1108
76. H.A. Malchow Crohn's disease and E. coli. A new approach in therapy to maintain remission of colonic Crohn's disease J Clin Gastroenterol 25 1997 653-658
77. O.C. Thompson-Chagoyán J. Maldonado A. Gil La microbiota intestinal en el niño y la influencia de la dieta sobre su composición Alim Nutr Salud 11 2004 37-48
78. I. Castagliuolo M.F. Riegler L. Valenick J.T. Lamont C. Pothoulakis Saccharomyces bourlardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa Infect Immun 67 1999 302-307
79. H. Ichikawa T. Kuroiwa A. Inagaki et al. Probiotic bacteria stimulate gut epithelial cell proliferation in rat Dig Dis Sci 44 1999 2119-2123
80. W.E. Roediger The colonic epithelium in ulcerative colitis: An energy-deficient disease? Lancet 2 1980 712.5
81. D.R. Mack S. Michail S. Wei L. McDougall M.A. Hollingsworth Probiotics inhibit enteropathogenic E coli adherence in vitro by inducing intestinal mucin gene expression Am J Physiol 276 1999 G941-G950